参考文献

［1］ICH. Q7: good manufacturing practice guide for active pharmaceutical ingredients.(2000-11-10)[2023-08-29]. https://database. ich. org/sites/default/ fi les/Q7%20Guideline. pdf.

［2］国家市场监督管理总局: 药品注册管理办法(总局令27号).(2020-01-22)[2023-08-29]. https://www. gov.cn/gongbao/content/2020/content_5512563. htm.

［3］国家药品监督管理局. 化学药品注册分类及申报资料要求(2020年第44号).[2023-08-29]. https://www.nmpa. gov. cn/yaopin/ypggtg/ypqtgg/20200630180301525. html.

［4］ICH. ICH Q8 (R2): pharmaceutical development.[2023-08-29]. https://database. ich. org/sites/default/ fi les/Q8%28R2%29%20Guideline. pdf.

［5］ICH. ICH Q9: quality risk management.(2023-01-18)[2023-08-29]. https://database. ich. org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2023_0126_0. pdf.

［6］ICH. ICH Q10: pharmaceutical quality system.(2008-06-04)[2023-08-29]. https://database. ich. org/sites/default/ fi les/Q10%20Guideline. pdf.

［7］FDA. Guidance for industry process validation: general principles and practices. 2011.

［8］ICH. ICH Q11: development and manufacture of drug substances.(2012-05-01)[2023-08-29]. https://database. ich. org/sites/default/ fi les/Q11%20Guideline. pdf.

［9］ICH. ICH Q11: questions and answers.(2017-08-23)[2023-08-29]. https://database. ich. org/sites/default/files/Q11_Q%26As_Q%26As. pdf.

［10］国家药品监督管理局. 化学药物原料药制备和结构确证研究的技术指导原则.(2005-03-18)[2023-08-29].https://www. nmpa. gov. cn/wwwroot/gsz05106/02. pdf.

［11］康建磊. CTD格式申报资料中原料药特性鉴定部分的解读. 中国新药杂志, 2016, 25 (18): 2109-2112.

［12］ICH. ICHQ6A: speci fi cations: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances.(1999-10-04)[2023-08-29]. https://database. ich. org/sites/default/ fi les/Q6A%20Guideline. pdf.

［13］国家药典委员会. 中华人民共和国药典: 2020年版. 北京: 中国医药科技出版社, 2020.

［14］ICH. ICH Q3A (R2): impurities in new drug substances.(2006-10-25)[2023-08-29]. https://database. ich.org/sites/default/ fi les/Q3A%28R2%29%20Guideline. pdf.

［15］康建磊. 浅谈化学合成原料药的杂质谱分析. 中国医药工业杂志, 2016, 47 (8): 1093-1096.

［16］ICH. ICH Q1A (R2): stability testing of new drug substances and products.(2003-02-06)[2023-08-29].https://database. ich. org/sites/default/f i les/Q1A%28R2%29%20Guideline. pdf.

［17］ICH. ICHQ3C (R8): impurities: guideline for residual solvents.(2021-04-22)[2023-08-29]. https://database. ich. org/sites/default/f i les/ICH_Q3C-R8_Guideline_Step4_2021_0422. pdf.

［18］国家药品监督管理局. 化学药物残留溶剂研究的技术指导原则.(2005-03-18)[2023-8-29]. https://www.nmpa. gov. cn/wwwroot/gsz05106/06. pdf.

［19］ICH. ICH Q3D (R2): guideline for elemental impurities.(2022-04-26)[2023-08-29]. https://database. ich.org/sites/default/f i les/Q3D-R2_Guideline_Step4_2022_0308. pdf.

［20］ICH. ICHM7: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk.(2023-04-03)[2023-08-29]. https://database. ich. org/sites/default/files/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0. pdf.

［21］ICH. ICH M7 (R2): addendum to M7.(2023-04-03)[2023-08-29]. https://database. ich. org/sites/default/files/ICH_M7%28R2%29_Addendum_Step4_2023_0531_0. pdf.